Drugs.com - New Drug Approvals

FDA Grants Interchangeable Designation to Yuflyma (adalimumab-aaty), Celltrion's Biosimilar to Humira (adalimumab)

INCHEON, South Korea, April 14, 2025 /-- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated Yuflyma® (adalimumab-aaty), as an interchangeable biosimilar to Humira® (adalimumab). Yuflyma is an...

Apr 15, 2025 - 04:46
 0
FDA Grants Interchangeable Designation to Yuflyma (adalimumab-aaty), Celltrion's Biosimilar to Humira (adalimumab)
INCHEON, South Korea, April 14, 2025 /-- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated Yuflyma® (adalimumab-aaty), as an interchangeable biosimilar to Humira® (adalimumab). Yuflyma is an...
Read More

Tags:

Previous Article

Qatar’s Hamad Airport Holds Firm In New Rankings As Duty-Free Expands

Next Article

Beauty M&A Faces Further Uncertainty Amid Tariffs

Related Posts

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

Apr 15, 2025  0

FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease

FDA Approves Tremfya (guselkumab) for Adult Patients wi...

Mar 24, 2025  0

FDA Approves Grafapex (treosulfan) Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

FDA Approves Grafapex (treosulfan) Preparative Regimen ...

Feb 9, 2025  0